These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 21458643)
1. [Prevention of progression and regression of target organ damage. Future strategies]. de la Sierra A Rev Clin Esp; 2011 Mar; 211 Suppl 1():8-14. PubMed ID: 21458643 [TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives. de la Sierra A Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1585-91. PubMed ID: 22103877 [TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Ruilope LM Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118 [TBL] [Abstract][Full Text] [Related]
5. [The future of renin inhibition]. Uresin AY; Baran E Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475 [TBL] [Abstract][Full Text] [Related]
6. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?]. Horký K Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167 [TBL] [Abstract][Full Text] [Related]
7. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases]. Horký K Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582 [TBL] [Abstract][Full Text] [Related]
10. [Renin-angiotensin system modulation: instructions for use]. Bellis A; Rozza F; Crispo S; Trimarco B G Ital Cardiol (Rome); 2008 Feb; 9(2):79-89. PubMed ID: 18383770 [TBL] [Abstract][Full Text] [Related]
11. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Tocci G; Sciarretta S; Facciolo C; Volpe M Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654 [TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy. Giles TD Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312 [TBL] [Abstract][Full Text] [Related]
13. [Inhibition of the renin-angiotensin system to prevent target organ damage: the "renal continuum"]. Tislér A Orv Hetil; 2003 May; 144(18 Suppl 1):898-901. PubMed ID: 12785234 [TBL] [Abstract][Full Text] [Related]
15. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension]. Abassi Z; Armaly Z; Nakhoul F; Hoffman A Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632 [TBL] [Abstract][Full Text] [Related]
16. Blocking the renin-angiotensin system: dual- versus mono-therapy. Ravandi A; Teo KK Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282 [TBL] [Abstract][Full Text] [Related]
17. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Weber MA; Giles TD Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123 [TBL] [Abstract][Full Text] [Related]
18. Recent changes in the landscape of combination RAS blockade. Epstein BJ; Smith SM; Choksi R Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020 [TBL] [Abstract][Full Text] [Related]
19. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?]. Dussol B; Berland Y Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now? Böhm M Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]